WO2016195070A1 - 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 - Google Patents
還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 Download PDFInfo
- Publication number
- WO2016195070A1 WO2016195070A1 PCT/JP2016/066586 JP2016066586W WO2016195070A1 WO 2016195070 A1 WO2016195070 A1 WO 2016195070A1 JP 2016066586 W JP2016066586 W JP 2016066586W WO 2016195070 A1 WO2016195070 A1 WO 2016195070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reduced glutathione
- crystal
- type
- crystals
- aqueous solution
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
- C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
Definitions
- the present invention relates to a method for producing ⁇ -type crystals of reduced glutathione and a method for storing the crystals.
- Reduced glutathione is a tripeptide composed of three types of amino acids (glutamic acid, cysteine and glycine), and has been used as a raw material for pharmaceuticals and health foods as a material having an antioxidant function and a detoxifying action. In recent years, it is expected to expand to other diverse markets such as beverages and cosmetics.
- Non-patent Document 1 There are two types of crystal polymorphs, ⁇ -type crystals and ⁇ -type crystals, in reduced glutathione crystals (Non-patent Document 1).
- the ⁇ -type crystal which is an unstable crystal and the ⁇ -type crystal which is a stable crystal are greatly different in solubility, and the saturated solubility at 10 ° C. is 89 g / L for the ⁇ -type crystal and 30 g / L for the ⁇ -type crystal ( FIG. 1). Therefore, the ⁇ -type crystal having low solubility has a problem that it is difficult to process as a raw material and is difficult to handle. Furthermore, needle-shaped and small ⁇ -type crystals are inferior to ⁇ -type crystals in terms of both quality and productivity because they are poor in separability from mother liquor, whereas ⁇ -type crystals that are columnar crystals that tend to be large.
- Non-Patent Document 2 a method for controlling the occurrence of crystal polymorphism of organic compounds including amino acids
- addition of a crystallizing agent may be effective (Patent Document 1, Non-Patent Document 2).
- the chemical structure of the compound added as the crystallization agent has extremely high similarity to the chemical structure of the target compound (Non-Patent Document 2)
- the molecular weight of the crystal clearing agent is subject to severe restrictions such as the molecular weight of the target compound must be the same or slightly smaller (Non-patent Document 3). Because of these restrictions, compounds with low structural similarity and compounds with a molecular weight that is far from the target compound are generally excluded from the target for the search for the crystal modifier.
- An object of the present invention is to provide a method for efficiently and stably producing reduced ⁇ -type crystals of reduced glutathione that are excellent in both quality and productivity and a storage method.
- the present inventors have studied to solve the above-mentioned problems, and by causing a solution of a reduced glutathione in an aqueous solution and an ⁇ -type crystal to coexist with a crystallization agent, the generation of the ⁇ -type crystal and the transition to the ⁇ -type crystal are remarkable.
- the generation of ⁇ -type crystal and the transition to the ⁇ -type crystal are remarkable.
- by performing crystallization of ⁇ -type crystals of reduced glutathione in the presence of a crystallization agent compared to the case where no crystallization agent is added, the generation of ⁇ -type crystals and ⁇
- the present inventors have found that the transition to a type crystal is remarkably suppressed and that an ⁇ type crystal can be produced efficiently and stably.
- the present invention is as follows.
- [1] Generation of ⁇ -form crystals of reduced glutathione and / or ⁇ of reduced glutathione comprising at least one compound selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds and dipeptides
- [2] ⁇ -type crystals of reduced glutathione containing the crystal clearing agent according to [1] above.
- [3] The crystal according to the above [2], wherein the content of the crystallization agent is 0.01 to 10% by weight with respect to the ⁇ -type crystal of reduced glutathione.
- An ⁇ -type crystal of reduced glutathione comprising a step of adding the crystallizing agent according to [1] above to an aqueous solution containing reduced glutathione and a step of crystallizing ⁇ -type crystals of reduced glutathione.
- Production method [5] The method of the above-mentioned [4], wherein the addition amount of the crystallization agent is 0.01 to 10% by weight with respect to reduced glutathione.
- a method for preserving an aqueous solution of reduced glutathione comprising a step of adding the crystallizing agent according to the above [1] to an aqueous solution of reduced glutathione.
- a specific crystal clearing agent is allowed to coexist, thereby generating a ⁇ -type crystal and converting the ⁇ -type crystal into a ⁇ -type crystal. Transition to the crystal is remarkably suppressed, and ⁇ -type crystal of reduced glutathione can be produced efficiently and stably.
- FIG. 1 is a graph showing the solubility curves of ⁇ -type crystals and ⁇ -type crystals of reduced glutathione.
- the vertical axis represents the solubility of each crystal in water (g / L) at each temperature, and the horizontal axis represents the temperature (° C.). Represents.
- reduced glutathione means a tripeptide composed of glutamic acid, cysteine and glycine as described above.
- the reduced glutathione used in the present invention may be obtained by any production method, and examples thereof include those obtained by the method described in JP-B-57-016196. it can.
- the term “medium crystallizer” generally means an additive added to change the crystal habit of a parent compound or to prevent polymorphic transition.
- reduced glutathione It means a compound that suppresses the generation of ⁇ -type crystals of reduced glutathione or inhibits the transfer of reduced glutathione from ⁇ -type crystals to ⁇ -type crystals during the production and storage of ⁇ -type crystals.
- the crystal clearing agent used in the present invention include aliphatic amino acids such as alanine and proline, sulfur-containing amino acids such as cysteine, aromatic amino acids such as phenylalanine and tryptophan, related compounds such as oxidized glutathione, and dipeptides such as alanylcysteine.
- At least one crystal clearing agent selected from the group consisting of L-cysteine, L-alanine, L-phenylalanine, L-tryptophan and D-proline, oxidized glutathione and L-alanyl-L-cysteine is particularly preferable.
- the crystallizing agent may be obtained by any production method, and examples thereof include those obtained by a chemical synthesis method, an extraction method, and a fermentation method.
- aliphatic amino acid means a hydrophobic amino acid that does not contain an aromatic amino acid.
- examples of the aliphatic amino acid include glycine, alanine, valine, leucine, isoleucine, proline and the like, among which L-alanine and D-proline are preferable.
- sulfur-containing amino acid means an amino acid having a sulfur atom in its structure.
- sulfur-containing amino acid include cysteine, homocysteine, methionine and the like, and among them, L-cysteine is preferable.
- aromatic amino acid means a hydrophobic amino acid having an aromatic ring and an aromatic heterocyclic ring.
- Aromatic amino acids include phenylalanine, tryptophan, tyrosine, etc. Among them, L-phenylalanine and L-tryptophan are preferable.
- oxidized glutathione means a molecule in which two molecules of reduced glutathione are linked by a disulfide bond.
- oxidized glutathione may be abbreviated as “GSSG”.
- dipeptide means a molecule in which two molecules of amino acids are linked by peptide bonds.
- examples of the dipeptide include L-alanine-L-glutamine, L-alanyl-L-cysteine, etc. Among them, L-alanyl-L-cysteine is preferable.
- aqueous solution means a solution containing only water as a solvent or a solution containing water as a main solvent.
- the aqueous solution may contain, for example, a water-soluble organic solvent such as methanol, ethanol, propanol, and acetone in addition to water as long as the effects of the present invention are not impaired.
- reduced glutathione aqueous solution or “aqueous solution containing reduced glutathione” is an aqueous solution containing at least dissolved reduced glutathione, and may be a solution in which reduced glutathione is completely dissolved. In addition to the dissolved reduced glutathione, ⁇ -type crystals of reduced glutathione may be included. (Preservation method of reduced glutathione aqueous solution of the present invention)
- the present invention relates to an aliphatic amino acid, a sulfur-containing amino acid, an aromatic amino acid, an analog, and the like in order to suppress the generation of ⁇ -type crystals, which are stable crystals in which crystals are easily precipitated in an aqueous solution.
- a method for preserving a reduced glutathione aqueous solution (hereinafter, referred to as “the aqueous solution preserving method of the present invention”) characterized in that any one or a plurality of compounds of compounds and dipeptides coexist as a crystal clearing agent. is there.
- the crystallization agent those described above can be suitably used.
- the reduced glutathione (containing) aqueous solution is at least one liquid crystal selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds and dipeptides, as long as the effects of the present invention are not impaired. Solutes other than may be included. Examples of such solutes include salts and buffering agents. Furthermore, the reduced glutathione (containing) aqueous solution may be a supernatant of a fermentation broth containing reduced glutathione, a reaction solution that produces reduced glutathione, or the like. Examples of the salt include sodium chloride and sodium sulfate, and examples of the buffer include sodium acetate and sodium bicarbonate.
- the crystallizing agent may be added to the reduced glutathione aqueous solution, or the reduced glutathione aqueous solution may be added to the crystallizing agent.
- a solid crystallizing agent is added, it is preferably dissolved after the addition to the reduced glutathione aqueous solution.
- the crystal clearing agent of the present invention can coexist in any step as long as the production of reduced glutathione is not prevented.
- the crystallizing agent of the present invention can be allowed to coexist with reduced glutathione produced from the raw material.
- the generation of ⁇ -type crystals and / or the transition from ⁇ -type crystals to ⁇ -type crystals are suppressed for a longer time in the presence of a crystal clearing agent than in the case of non-coexistence. Can do.
- the temperature of the reduced glutathione aqueous solution is not particularly limited as long as the generation of ⁇ -type crystals and / or the transition from ⁇ -type crystals to ⁇ -type crystals does not occur. Is preferable in terms of suppression of metastasis.
- the temperature of the reduced glutathione aqueous solution in which generation of ⁇ -type crystals and / or transition to ⁇ -type crystals does not occur depends on the type or concentration of the crystallizing agent, but is usually 60 ° C. or less, preferably 40 ° C. or less. More preferably, it is 25 ° C. or less, particularly preferably 10 ° C. or less.
- the amount of the crystallizing agent added to the reduced glutathione aqueous solution is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1% by weight with respect to the reduced glutathione. % Or more. Moreover, it is desirable that it is 10 weight% or less.
- a suitable addition amount of the crystallizing agent can be determined, for example, as follows.
- a crystallizing agent is added to the reduced glutathione aqueous solution so as to be about 5% by weight or less, and stirred for a predetermined time.
- the crystals precipitated during stirring are observed with a microscope to determine whether all the crystals are ⁇ -type crystals, or ⁇ -type crystals are generated or transition to ⁇ -type crystals. Since the ⁇ -type crystal, which is a large columnar crystal, and the ⁇ -type crystal, which is a small needle crystal, are greatly different in shape, they can be easily distinguished by microscopic observation.
- the crystals obtained by separating a part are dissolved in water at 25 ° C. so as to be 100 g / L. After stirring and holding for a sufficient time, the solution is tested with a cell having a layer length of 1 cm, using water as a control, by the visible absorbance measurement method, and the transmittance at 430 nm is measured to confirm turbidity.
- ⁇ -type crystals with low solubility are present, undissolved crystals are detected as turbidity, and the transmittance of the solution is lowered.
- concentration of reduced glutathione in the solution in the crystallization and slurry is lower than that in the solution containing only ⁇ -type crystals, so the reduced form in the mother liquor from which the coexisting crystals have been removed.
- the type of coexisting crystals can also be determined by measuring the glutathione concentration.
- the reduced glutathione concentration in the mother liquor is measured using the following HPLC conditions after the coexisting crystals are removed by filtration or the like, diluted to a constant concentration with a mobile phase, and stirred for a sufficient time.
- HPLC condition column Inertsil ODS-3 ID 3.0 mm, length 150 mm Column temperature: 35 ° C Detector: UV detector, wavelength 210nm
- Mobile phase composition 1-sodium heptanesulfonate / potassium dihydrogen phosphate / phosphoric acid / methanol
- each crystallization component contained in the reduced glutathione aqueous solution for example, about 0.25 g of a sample is precisely weighed and dissolved in pure water, and the volume is adjusted to 25 mL and 1 mL is collected. Add dilution buffer and adjust the volume to 10 mL, then centrifuge the fixed volume at 10000 rpm for 5 minutes, introduce the supernatant into amino acid analyzer JLC-500V (manufactured by JEOL Ltd.), and measure according to the instructions You can also ( ⁇ -type crystal of reduced glutathione of the present invention)
- the present invention is an ⁇ -type crystal of reduced glutathione (hereinafter also referred to as “ ⁇ -type crystal of the present invention”) containing the above-mentioned crystal clearing agent.
- the ⁇ -type crystal of reduced glutathione means that the diffraction angle 2 ⁇ is 6.3 °, 12.6 °, 13.8 °, 16.2 °, 22.3 °, 25.7 ° in powder X-ray diffraction. It is a crystal having peaks at 30.1 °, 31.9 °, 32.0 ° and 33.5 °.
- the content of the crystallization agent contained in the ⁇ -type crystal of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, based on the ⁇ -type crystal of reduced glutathione. It is particularly preferably 1.0% by weight or more. Moreover, it is desirable that it is 10 weight% or less.
- the ⁇ -type crystal of the present invention contains the above-mentioned crystal clearing agent, so that the transition to ⁇ -type crystal having low solubility and difficult to process as a raw material is suppressed.
- the amount of the crystallizing agent contained in the ⁇ -type crystal of the present invention was determined by diluting the ⁇ -type crystal of the present invention to a constant concentration with a mobile phase, holding the mixture for a sufficient time, and then using the following HPLC conditions. It can be determined by measuring the concentration.
- HPLC condition column YMC Triart C18 ID 3.0 mm, length 150 mm Column temperature: 40 ° C Detector: Fluorescence detector Excitation wavelength 360nm / Fluorescence wavelength 440nm
- Mobile phase composition trisodium citrate dihydrate / anhydrous sodium sulfate / n-propanol / sodium lauryl sulfate
- each crystallizing agent component contained in the ⁇ -type crystal of the present invention for example, about 0.25 g of a sample is precisely weighed, dissolved in pure water, then adjusted to 25 mL, and 1 mL is collected. Add dilution buffer and adjust the volume to 10 mL, then centrifuge the fixed volume at 10000 rpm for 5 minutes, introduce the supernatant into amino acid analyzer JLC-500V (manufactured by JEOL Ltd.), and measure according to the instructions You can also (Preservation method of ⁇ -form crystal of reduced glutathione of the present invention)
- the present invention relates to an ⁇ -form crystal of reduced glutathione, from an aliphatic amino acid, a sulfur-containing amino acid, an aromatic amino acid, an analogous compound, and a dipeptide in order to suppress the transition to a ⁇ -form crystal that has low solubility and is difficult to process as a raw material.
- the method for preserving ⁇ -type crystals of the present invention hereinafter referred to as “the method for preserving ⁇ -type crystals of the present invention”.
- the crystallization agent those described above can be suitably used.
- the ⁇ -type crystal of reduced glutathione is one kind selected from the group consisting of reduced glutathione and aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides, as long as the effects of the present invention are not impaired.
- a substance other than a plurality of types of crystallization agents may be included. Examples of such substances include salts, organic solvents and related compounds.
- a crystal modifier is allowed to coexist in the ⁇ -type crystal of the reduced glutathione.
- the ⁇ -type crystal of reduced glutathione is suspended in the solution of the crystallization agent, and then the crystal is separated. Crystals coexisting with the crystallization agent may be obtained, or crystals containing the crystallization agent may be obtained by spraying a solution containing the crystallization agent on ⁇ -type crystals of reduced glutathione.
- the generation of ⁇ -type crystals and / or the transition from ⁇ -type crystals to ⁇ -type crystals are suppressed for a longer time in the presence of a crystallization agent than in the case of non-coexistence. can do.
- the storage temperature of ⁇ -type crystals of reduced glutathione is not particularly limited as long as generation of ⁇ -type crystals and / or transition from ⁇ -type crystals to ⁇ -type crystals does not occur. A lower temperature is preferable in terms of suppression of transition.
- the storage temperature of the ⁇ -type crystal of reduced glutathione that does not generate and / or transfer to the ⁇ -type crystal varies depending on the type or concentration of the crystal clearing agent. It is below, Preferably it is 40 degrees C or less, More preferably, it is 25 degrees C or less, Most preferably, it is 10 degrees C or less.
- the addition amount of the crystallizing agent coexisting with the ⁇ -type crystal of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more with respect to the ⁇ -type crystal of reduced glutathione. It is particularly preferably 1.0% by weight or more. Moreover, it is desirable that it is 10 weight% or less.
- the amount of the crystallization agent coexisting with the ⁇ -form crystal of reduced glutathione is determined by diluting the ⁇ -form crystal of reduced glutathione coexisting with the crystallization agent with a mobile phase to a certain concentration, and stirring for a sufficient time. It can be determined by measuring the concentration using the following HPLC conditions.
- HPLC condition column YMC Triart C18 ID 3.0 mm, length 150 mm Column temperature: 40 ° C Detector: Fluorescence detector Excitation wavelength 360nm / Fluorescence wavelength 440nm
- Mobile phase composition trisodium citrate dihydrate / anhydrous sodium sulfate / n-propanol / sodium lauryl sulfate
- the present invention relates to an ⁇ -form crystal of reduced glutathione from an aqueous solution of reduced glutathione in the presence of at least one medium crystallizing agent selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds and dipeptides.
- at least one medium crystallizing agent selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds and dipeptides.
- the crystallizing agent may be added to the reduced glutathione aqueous solution, or the reduced glutathione may be added to the crystallizing agent solution.
- the crystallizing agent to be added may be a solid or a solution. When a solid crystallizing agent is added, it is preferably dissolved after the addition to the reduced glutathione aqueous solution.
- the crystal clearing agent of the present invention can coexist in any step as long as the production of reduced glutathione is not prevented.
- the crystallizing agent of the present invention can be allowed to coexist with reduced glutathione produced from the raw material.
- the crystallizing agent may be contained in the reduced glutathione aqueous solution before crystallization, or after the ⁇ -type crystals of the reduced glutathione are precipitated, the transition to the ⁇ -type crystals starts. It may be added before.
- concentration crystallization is performed by concentrating a reduced glutathione aqueous solution
- cooling crystallization is performed by cooling the reduced glutathione aqueous solution, or reduced crystallization.
- It can be performed by a poor solvent crystallization in which crystallization is performed by adding a poor solvent to the glutathione aqueous solution, or a method in which these are combined.
- the poor solvent include alcohols having 1 to 6 carbon atoms, acetone, methyl ethyl ketone, and diethyl ketone.
- the crystals of the reduced glutathione Crystallize By concentrating or cooling the reduced glutathione aqueous solution and increasing the reduced glutathione concentration above the saturation solubility, or by adding a poor solvent to the reduced glutathione aqueous solution to reduce the saturation solubility, the crystals of the reduced glutathione Crystallize.
- at least one crystallizing agent selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds and dipeptides compared with the case of non-coexistence, Generation of ⁇ -type crystals over a longer period of time and transition to ⁇ -type crystals after precipitation of ⁇ -type crystals can be suppressed, so that ⁇ -type crystals can be obtained efficiently and stably.
- ⁇ -type crystals of reduced glutathione may be added as seed crystals prior to or during the concentration of the reduced glutathione aqueous solution, the cooling operation or the addition of the poor solvent, or during these operations.
- the ⁇ -type crystal of reduced glutathione can be obtained, for example, by crystallization at 25 ° C. or lower from a reduced glutathione aqueous solution.
- a reduced glutathione aqueous solution is concentrated to precipitate a part of the reduced glutathione as ⁇ -type crystals, and the resulting slurry is cooled to dissolve dissolved reduced glutathione. Is further precipitated as ⁇ -type crystals.
- a crystal clearing agent before or after concentration of the reduced glutathione aqueous solution, or at least before the crystals of reduced glutathione crystallize.
- the temperature at which the ⁇ -type crystal of reduced glutathione is crystallized is not particularly limited as long as the generation of the ⁇ -type crystal and / or the transition from the ⁇ -type crystal to the ⁇ -type crystal does not occur.
- a lower temperature is preferable in terms of yield.
- the temperature for crystallization of the ⁇ -type crystal of reduced glutathione that does not cause the generation of ⁇ -type crystals and / or the transition from ⁇ -type crystals to ⁇ -type crystals varies depending on the type or concentration of the crystal clearing agent, and is appropriately set. Although it is desirable, it is preferably 40 ° C or lower, more preferably 25 ° C or lower, and particularly preferably 10 ° C or lower.
- the concentration of the crystallizing agent coexisting in the reduced glutathione aqueous solution is preferably 0.01% by weight with respect to the reduced glutathione when the crystallization temperature is 25 ° C. and the crystallization time is 24 hours or more. % Or more, more preferably 0.1% by weight or more, and particularly preferably 1.0% by weight or more. Moreover, it is desirable that it is 10 weight% or less.
- the type of crystallization agent the temperature at which crystallization is performed, the type and concentration of components other than the reduced glutathione and the crystallization agent contained in the reduced glutathione aqueous solution, the generation of ⁇ crystals by the crystallization agent and the ⁇ type
- the inhibitory effect of the transition to crystals can vary.
- the suitable addition amount of the crystallization agent is appropriately set according to the reduced glutathione aqueous solution to which the present invention is applied, the type and concentration of the crystallization agent used, and the crystallization temperature. In order to extend the time for generating the ⁇ -type crystal or the transition from the ⁇ -type crystal to the ⁇ -type crystal, it is preferable to increase the concentration of the crystallizing agent.
- the ⁇ -type crystal of reduced glutathione is obtained by separating the crystal from the mother liquor.
- the ⁇ -type crystal can remove excess crystallization agent and impurities by recrystallization or crystal washing.
- the obtained ⁇ -type crystal is desirably dried to prevent further transition to the ⁇ -type crystal.
- the drying temperature only needs to be a temperature at which reduced glutathione does not decompose, and is preferably 100 ° C. or lower, more preferably 60 ° C. or lower, and particularly preferably 25 ° C. or lower.
- the dried ⁇ -form crystals of reduced glutathione can be appropriately packaged to obtain a final product.
- L-alanine hereinafter sometimes abbreviated as L-Ala
- L-cysteine hereinafter also abbreviated as L-Cys
- L-phenylalanine hereinafter abbreviated as L-Phe
- L-tryptophan hereinafter also abbreviated as L-Trp
- D-proline hereinafter also abbreviated as D-Pro
- AlaCys L-alanyl-L-cysteine
- L-His L-histidine hydrochloride
- the amount of the crystallizing agent added to the aqueous solution of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, based on the reduced glutathione. Particularly preferably, it was found to be 1% by weight or more.
- Reduced glutathione (50 g) and water (500 mL) were added to a 1 L beaker.
- 2.5 g each of L-alanine, L-cysteine or oxidized glutathione was added to the prepared solution, heated at 40 ° C. to completely dissolve the crystals, and filtered using a membrane filter.
- the reduced glutathione concentration in the prepared solution (filtrate) was concentrated by an evaporator so that the saturated solubility of ⁇ -type crystals was equal to or higher than that of the ⁇ -type crystals, and concentrated crystallization of reduced glutathione was performed.
- the concentrated solution was cooled to 25 ° C. and stirred for 24 hours, and then the crystals in the slurry were observed with a microscope to determine the presence or absence of transition to ⁇ -type crystals.
- Reduced glutathione (50 g) and water (500 mL) were added to a 1 L beaker. 10% by weight of L-alanine or L-cysteine was added to the prepared solution, respectively, with respect to reduced glutathione, heated at 40 ° C. to completely dissolve the crystals, and filtered using a membrane filter.
- the reduced glutathione concentration in the prepared solution (filtrate) was concentrated by an evaporator so that the saturated solubility of ⁇ -type crystals was equal to or higher than that of the ⁇ -type crystals, and concentrated crystallization of reduced glutathione was performed.
- the concentrate was cooled to 25 ° C. and stirred for 24 hours, and then the presence or absence of transition to ⁇ -type crystals was determined by observing the crystals in the slurry under a microscope.
- ⁇ -type crystal of reduced glutathione when a reduced glutathione ⁇ -type crystal is produced (crystallized) and stored, a specific crystal clearing agent or preservative is allowed to coexist, thereby generating ⁇ -type crystals and ⁇ -type crystals.
- the ⁇ -type crystal of reduced glutathione can be produced efficiently and stably.
- ⁇ -type crystals of reduced glutathione that are excellent in both quality and productivity can be stably supplied, and thus are useful in various fields such as pharmaceuticals, foods, and cosmetics.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[1]脂肪族アミノ酸、含硫アミノ酸、芳香族アミノ酸、類縁化合物及びジペプチドからなる群より選択される少なくとも1つの化合物からなる、還元型グルタチオンのβ型結晶の発生及び/又は還元型グルタチオンのα型結晶からβ型結晶への転移を抑制するための媒晶剤。
[2]上記[1]記載の媒晶剤を含有する、還元型グルタチオンのα型結晶。
[3]媒晶剤の含有量が、還元型グルタチオンのα型結晶に対して0.01~10重量%である、上記[2]記載の結晶。
[4]還元型グルタチオンを含有する水溶液に、上記[1]記載の媒晶剤を添加する工程、及び還元型グルタチオンのα型結晶を晶析させる工程を含む、還元型グルタチオンのα型結晶の製造方法。
[5]媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、上記[4]記載の方法。
[6]還元型グルタチオンの水溶液に、上記[1]記載の媒晶剤を添加する工程を含む、還元型グルタチオンの水溶液の保存方法。
[7]媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、上記[6]記載の方法。
[8]還元型グルタチオンのα型結晶に、上記[1]記載の媒晶剤を添加する工程を含む、還元型グルタチオンのα型結晶の保存方法。
[9]媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、上記[8]記載の方法。
(定義)
(本発明の還元型グルタチオン水溶液の保存方法)
カラム:Inertsil ODS-3 内径3.0mm、長さ150mm
カラム温度:35℃
検出器:UV検出器 波長210nm
移動相組成:1-ヘプタンスルホン酸ナトリウム/リン酸二水素カリウム/リン酸/メタノール
(本発明の還元型グルタチオンのα型結晶)
カラム:YMC Triart C18 内径3.0mm、長さ150mm
カラム温度:40℃
検出器:蛍光検出器 励起波長360nm/蛍光波長440nm
移動相組成:クエン酸三ナトリウム二水和物/無水硫酸ナトリウム/n-プロパノール/ラウリル硫酸ナトリウム
(本発明の還元型グルタチオンのα型結晶の保存方法)
カラム:YMC Triart C18 内径3.0mm、長さ150mm
カラム温度:40℃
検出器:蛍光検出器 励起波長360nm/蛍光波長440nm
移動相組成:クエン酸三ナトリウム二水和物/無水硫酸ナトリウム/n-プロパノール/ラウリル硫酸ナトリウム
(本発明の還元型グルタチオンのα型結晶の製造方法)
還元型グルタチオンのα型結晶の保存時における媒晶剤の添加によるβ型結晶への転移抑制効果の確認試験
還元型グルタチオンのα型結晶の保存時における媒晶剤の添加によるβ型結晶の発生抑制効果の確認試験
還元型グルタチオン水溶液の保存時における媒晶剤の添加効果の確認試験
還元型グルタチオン水溶液の保存時のβ型結晶の発生の抑制に必要な媒晶剤の添加量の検討
還元型グルタチオンのα型結晶の製造方法(1)
還元型グルタチオンのα型結晶の製造方法(2)
L-アラニン又はL-システインをそれぞれ10重量%添加して晶析させることにより取得した結晶は、共に粉末X線回折において、回折角2θが、6.3°、12.6°、13.8°、16.2°、22.3°、25.7°、30.1°、31.9°、32.0°及び33.5°にピークを有する還元型グルタチオンのα型結晶であることが分かった。
Claims (9)
- 脂肪族アミノ酸、含硫アミノ酸、芳香族アミノ酸、類縁化合物及びジペプチドからなる群より選択される少なくとも1つの化合物からなる、還元型グルタチオンのβ型結晶の発生及び/又は還元型グルタチオンのα型結晶からβ型結晶への転移を抑制するための媒晶剤。
- 請求項1記載の媒晶剤を含有する、還元型グルタチオンのα型結晶。
- 媒晶剤の含有量が、還元型グルタチオンのα型結晶に対して0.01~10重量%である、請求項2記載の結晶。
- 還元型グルタチオンを含有する水溶液に、請求項1記載の媒晶剤を添加する工程、及び還元型グルタチオンのα型結晶を晶析させる工程を含む、還元型グルタチオンのα型結晶の製造方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、請求項4記載の方法。
- 還元型グルタチオンの水溶液に、請求項1記載の媒晶剤を添加する工程を含む、還元型グルタチオンの水溶液の保存方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、請求項6記載の方法。
- 還元型グルタチオンのα型結晶に、請求項1記載の媒晶剤を添加する工程を含む、還元型グルタチオンのα型結晶の保存方法。
- 媒晶剤の添加量が、還元型グルタチオンに対して0.01~10重量%である、請求項8記載の方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201680032873.8A CN107636006B (zh) | 2015-06-05 | 2016-06-03 | 还原型谷胱甘肽的α型晶体的生产方法和所述晶体的保存方法 |
JP2017522276A JP6868556B2 (ja) | 2015-06-05 | 2016-06-03 | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 |
EP16803501.2A EP3305801A4 (en) | 2015-06-05 | 2016-06-03 | PROCESS FOR PREPARING AN ALPHA FORM CRYSTAL FROM REDUCED GLUTATHION AND METHOD FOR STORING THE SAID CRYSTAL |
US15/579,592 US10407463B2 (en) | 2015-06-05 | 2016-06-03 | Method for producing alpha-form crystal of reduced glutathione, and method for storing said crystal |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015114855 | 2015-06-05 | ||
JP2015-114855 | 2015-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016195070A1 true WO2016195070A1 (ja) | 2016-12-08 |
Family
ID=57441284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/066586 WO2016195070A1 (ja) | 2015-06-05 | 2016-06-03 | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US10407463B2 (ja) |
EP (1) | EP3305801A4 (ja) |
JP (2) | JP6868556B2 (ja) |
CN (1) | CN107636006B (ja) |
WO (1) | WO2016195070A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10858393B2 (en) | 2016-03-17 | 2020-12-08 | Kyowa Hakko Bio Co., Ltd. | Crystal of reduced glutathione and method for producing same |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754717A (zh) * | 2021-10-15 | 2021-12-07 | 南京高新工大生物技术研究院有限公司 | 一种还原型谷胱甘肽α型晶体的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61282397A (ja) * | 1985-06-07 | 1986-12-12 | Kohjin Co Ltd | グルタチオン及びγ−グルタミルシステインの精製法 |
JPH05339286A (ja) * | 1992-06-10 | 1993-12-21 | Kazuoki Ishihara | 還元型グルタチオンの安定化法および安定化組成物 |
JP5243963B2 (ja) * | 2006-10-16 | 2013-07-24 | 協和発酵バイオ株式会社 | グルタチオンの結晶およびその製造法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5125908B2 (ja) | 2008-09-05 | 2013-01-23 | 味の素株式会社 | シトルリンの晶析方法 |
JP2011223896A (ja) * | 2010-04-15 | 2011-11-10 | Ajinomoto Co Inc | ペプチドの製造方法 |
-
2016
- 2016-06-03 US US15/579,592 patent/US10407463B2/en active Active
- 2016-06-03 WO PCT/JP2016/066586 patent/WO2016195070A1/ja active Application Filing
- 2016-06-03 EP EP16803501.2A patent/EP3305801A4/en not_active Withdrawn
- 2016-06-03 CN CN201680032873.8A patent/CN107636006B/zh active Active
- 2016-06-03 JP JP2017522276A patent/JP6868556B2/ja active Active
-
2021
- 2021-02-15 JP JP2021021715A patent/JP2021080265A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61282397A (ja) * | 1985-06-07 | 1986-12-12 | Kohjin Co Ltd | グルタチオン及びγ−グルタミルシステインの精製法 |
JPH05339286A (ja) * | 1992-06-10 | 1993-12-21 | Kazuoki Ishihara | 還元型グルタチオンの安定化法および安定化組成物 |
JP5243963B2 (ja) * | 2006-10-16 | 2013-07-24 | 協和発酵バイオ株式会社 | グルタチオンの結晶およびその製造法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10858393B2 (en) | 2016-03-17 | 2020-12-08 | Kyowa Hakko Bio Co., Ltd. | Crystal of reduced glutathione and method for producing same |
Also Published As
Publication number | Publication date |
---|---|
CN107636006A (zh) | 2018-01-26 |
US20180170959A1 (en) | 2018-06-21 |
US10407463B2 (en) | 2019-09-10 |
CN107636006B (zh) | 2021-11-09 |
EP3305801A4 (en) | 2019-01-23 |
JPWO2016195070A1 (ja) | 2018-03-22 |
EP3305801A1 (en) | 2018-04-11 |
JP6868556B2 (ja) | 2021-05-12 |
JP2021080265A (ja) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yang et al. | Effect of sodium chloride on the nucleation and polymorphic transformation of glycine | |
Kaptein et al. | Attrition‐enhanced deracemization of an amino acid derivative that forms an epitaxial racemic conglomerate | |
JP2021080265A (ja) | 還元型グルタチオンのα型結晶の製造方法及び当該結晶の保存方法 | |
WO2016121810A1 (ja) | N-アセチルノイラミン酸アンモニウム塩・無水和物の結晶及びその製造方法 | |
EP3150623A1 (en) | Solvate of cyclic peptide compound, preparation method for same, and uses thereof | |
Sun et al. | Additive-assisted preferential crystallization of racemic component: A case of norvaline | |
Elfassy et al. | Crystallization of amino acids at the chiral ionic liquid/water interface | |
US7820860B2 (en) | Method for separating compound-forming chiral systems | |
Vartak et al. | Surface functionalization in combination with confinement for crystallization from undersaturated solutions | |
O'Mahony et al. | Investigating the dissolution of the metastable triclinic polymorph of carbamazepine using in situ microscopy | |
JP6826267B2 (ja) | クエン酸誘導体のジアステレオマーの製造方法 | |
CN110114333B (zh) | 赖氨酸乙酰水杨酸盐·甘氨酸颗粒的改进合成 | |
Pons-Siepermann et al. | Purification of nitrophenols using complex-assisted crystallization | |
JP5125908B2 (ja) | シトルリンの晶析方法 | |
Chen et al. | Pasteur revisited: chiral separation by crystallization on self-assembled monolayers | |
Dhanasekaran et al. | Nucleation control, separation and bulk growth of metastable α-l-glutamic acid single crystals in the presence of l-tyrosine | |
JPS59227848A (ja) | ポリペプチド類の製造方法 | |
JP6716903B2 (ja) | ジペプチドの製造方法 | |
JP5596695B2 (ja) | エリスロマイシンの結晶化方法 | |
CN104592046B (zh) | 光学活性的缬氨酸复合物及其生产方法 | |
Sato et al. | New optical resolution method for racemic DL-aspartic acid by crystallization in the presence of d-or l-asparagine as a tailor-made additive | |
JPH04352796A (ja) | アスパルテームの晶析法 | |
HRP20020122A2 (en) | Methods for crystallization of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine n-carboxyanhydride | |
Yang et al. | Ternary phase diagram and the formation mechanism of two distinct solid solutions of amino acid systems: L-Valine/L-norvaline and L-valine/L-alanine | |
Abd Rahim et al. | Screening of carbamazepine-ibuprofen co-crystal formation using non-stoichiometric and stoichiometric methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16803501 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017522276 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15579592 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016803501 Country of ref document: EP |